Skip to main content
Journal cover image

Myasthenia gravis.

Publication ,  Journal Article
Juel, VC; Massey, JM
Published in: Orphanet J Rare Dis
November 6, 2007

Myasthenia gravis (MG) is a rare, autoimmune neuromuscular junction disorder. Contemporary prevalence rates approach 1/5,000. MG presents with painless, fluctuating, fatigable weakness involving specific muscle groups. Ocular weakness with asymmetric ptosis and binocular diplopia is the most typical initial presentation, while early or isolated oropharyngeal or limb weakness is less common. The course is variable, and most patients with initial ocular weakness develop bulbar or limb weakness within three years of initial symptom onset. MG results from antibody-mediated, T cell-dependent immunologic attack on the endplate region of the postsynaptic membrane. In patients with fatigable muscle weakness, the diagnosis of MG is supported by: 1. pharmacologic testing with edrophonium chloride that elicits unequivocal improvement in strength; 2. electrophysiologic testing with repetitive nerve stimulation (RNS) studies and/or single-fiber electromyography (SFEMG) that demonstrates a primary postsynaptic neuromuscular junctional disorder; and 3. serologic demonstration of acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies. Differential diagnosis includes congenital myasthenic syndromes, Lambert Eaton syndrome, botulism, organophosphate intoxication, mitochondrial disorders involving progressive external ophthalmoplegia, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), motor neuron disease, and brainstem ischemia. Treatment must be individualized, and may include symptomatic treatment with cholinesterase inhibitors and immune modulation with corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil. Rapid, temporary improvement may be achieved for myasthenic crises and exacerbations with plasma exchange (PEX) or intravenous immunoglobulin (IVIg). Owing to improved diagnostic testing, immunotherapy, and intensive care, the contemporary prognosis is favorable with less than five percent mortality and nearly normal life expectancy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Orphanet J Rare Dis

DOI

EISSN

1750-1172

Publication Date

November 6, 2007

Volume

2

Start / End Page

44

Location

England

Related Subject Headings

  • Myasthenia Gravis
  • Humans
  • Genetics & Heredity
  • Diagnosis, Differential
  • 3202 Clinical sciences
  • 3105 Genetics
  • 1199 Other Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Juel, V. C., & Massey, J. M. (2007). Myasthenia gravis. Orphanet J Rare Dis, 2, 44. https://doi.org/10.1186/1750-1172-2-44
Juel, Vern C., and Janice M. Massey. “Myasthenia gravis.Orphanet J Rare Dis 2 (November 6, 2007): 44. https://doi.org/10.1186/1750-1172-2-44.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007 Nov 6;2:44.
Juel, Vern C., and Janice M. Massey. “Myasthenia gravis.Orphanet J Rare Dis, vol. 2, Nov. 2007, p. 44. Pubmed, doi:10.1186/1750-1172-2-44.
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007 Nov 6;2:44.
Journal cover image

Published In

Orphanet J Rare Dis

DOI

EISSN

1750-1172

Publication Date

November 6, 2007

Volume

2

Start / End Page

44

Location

England

Related Subject Headings

  • Myasthenia Gravis
  • Humans
  • Genetics & Heredity
  • Diagnosis, Differential
  • 3202 Clinical sciences
  • 3105 Genetics
  • 1199 Other Medical and Health Sciences